Immune thrombocytopaenic purpura following the second dose of Pfizer COVID-19 vaccine

Immune thrombocytopaenic purpura (ITP) is often a diagnosis of exclusion with presentations ranging widely from asymptomatic patients to those with life-threatening bleeding. Secondary ITP following vaccination is relatively uncommon and underdiagnosed as majority of patients remain asymptomatic. Ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Latef, Taroob, Howard, Leslie, Loke, Chandravathi, Tsui, Edison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Case Reports: Unusual association of diseases/symptoms
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442476/
http://dx.doi.org/10.1136/bcr-2022-249477
Descripción
Sumario:Immune thrombocytopaenic purpura (ITP) is often a diagnosis of exclusion with presentations ranging widely from asymptomatic patients to those with life-threatening bleeding. Secondary ITP following vaccination is relatively uncommon and underdiagnosed as majority of patients remain asymptomatic. Cases of severe thrombocytopaenia associated with SARS-CoV-2 messenger RNA (ribonucleic acid) vaccinations have been described previously, mostly as isolated occurrences, and typically occurring following the first dose. Here we present a case of severe ITP associated with the second dose of the Pfizer-BioNTech/BNT16B2b2 mRNA vaccine and provide a review of the current literature.

Ejemplares similares